Flag of the European Union EU Clinical Trials Register Help

Clinical trials for NA NIS

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: NA NIS. Displaying page 1 of 1.
    EudraCT Number: 2007-006791-12 Sponsor Protocol Number: Fx1A-201 Start Date*: 2008-04-02
    Sponsor Name:FoldRx Pharmaceuticals Limited
    Full Title: The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients with Non-V30M Transthyretin Amyloidosis
    Medical condition: Non-V30M Transthyretin Amyloidosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001066-16 Sponsor Protocol Number: H23750 Start Date*: 2007-01-04
    Sponsor Name:John L. Berk, M.D.
    Full Title: The effect of diflunisal (IND 68092) on familial amyloidosis
    Medical condition: Familial Amyloid Polyneuropathy (FAP)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IT (Ongoing) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-002792-41 Sponsor Protocol Number: Fx-005 Start Date*: 2006-10-30
    Sponsor Name:FoldRx Pharmaceuticals Limited
    Full Title: Safety and Efficacy of Orally Administered Fx-1006A in Patients with Familial Amyloid Polyneuropathy (FAP): a Phase II/III, Randomised, Double-Blind, Placebo-Controlled Study
    Medical condition: Familial Amyloid Polyneuropathy (FAP).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057949 Familial amyloid polyneuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) PT (Completed) GB (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001831-30 Sponsor Protocol Number: ISIS420915-CS2 Start Date*: 2013-04-22
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy
    Medical condition: Familial Amyloid Polyneuropathy
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10057949 Familial amyloid polyneuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PT (Completed) DE (Completed) IT (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2005-000969-19 Sponsor Protocol Number: 6677889900 Start Date*: 2005-09-05
    Sponsor Name:Medizinische Klinik III, Kardiologie
    Full Title: Klinische Studie zur intraarteriellen Transplantation von Knochenmarks-Progenitorzellen bei Patienten mit Diabetischer Neuropathie (Restoration of Nerve functions by Intra-arterial ...
    Medical condition: Patienten mit Symptomen einer distal symmetrischen diabetischen Polyneuropathie der Beine (Stadium 2). Typischerweise bestehen Schmerzen, sowie Parästhesien und Sensibilitätsstörungen and der unter...
    Disease:
    Population Age: Adults, Elderly Gender:
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001262-87 Sponsor Protocol Number: Fx-006 Start Date*: 2008-07-04
    Sponsor Name:FoldRx Pharmaceuticals, Inc.
    Full Title: An Open-Label Extension of Study Fx-005 Evaluating Long-Term Safety and Clinical Outcomes of Fx-1006A in Patients with Transthyretin Amyloid Polyneuropathy
    Medical condition: Transthyretin Amyloid Polyneuropathy (ATTR-PN)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057949 Familial amyloid polyneuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) SE (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-006742-26 Sponsor Protocol Number: NIS-GEU-DUM-2008/1 Start Date*: 2009-01-08
    Sponsor Name:AstraZeneca AS
    Full Title: Symptomatic versus Endoscopic approach for the Diagnosis and Initial treatment of Gastroesophageal Reflux Disease using GerdQ
    Medical condition: Diagnosis and initial treatment of gastroesofageal reflux disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003865-11 Sponsor Protocol Number: NEOD001-CL002 Start Date*: 2015-11-27
    Sponsor Name:Prothena Therapeutics Limited
    Full Title: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chai...
    Medical condition: Light chain (AL) amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in bo...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10036673 Primary amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) ES (Completed) BE (Prematurely Ended) NL (Prematurely Ended) FR (Prematurely Ended) GB (Prematurely Ended) GR (Completed) PL (Prematurely Ended) DK (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005182-66 Sponsor Protocol Number: A4091029 Start Date*: 2009-05-04
    Sponsor Name:Pfizer Inc 235 East 42nd Street New York, NY 10017
    Full Title: PHASE II OPEN-LABEL SAFETY EXTENSION STUDY OF TANEZUMAB IN CANCER PATIENTS WITH PAIN DUE TO BONE METASTASES
    Medical condition: PAIN DUE TO BONE METASTASES
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049038 Metastatic bone pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LV (Completed) FR (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003519-24 Sponsor Protocol Number: ALN-TTR02-008 Start Date*: 2019-03-12
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients with Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Disease Progressi...
    Medical condition: Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    20.0 10010331 - Congenital, familial and genetic disorders 10019889 Hereditary neuropathic amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) PT (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-006226-49 Sponsor Protocol Number: NN6019-4940 Start Date*: 2022-08-18
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of NNC6019-0001 at two dose levels in participants with transthyretin amyloid cardiomyopathy (ATTR CM)
    Medical condition: Transthyretin amyloid cardiomyopathy (ATTR CM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10002020 Amyloid cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) PT (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-004007-19 Sponsor Protocol Number: AV-007-IM Start Date*: 2006-11-16
    Sponsor Name:Nycomed Austria GmbH
    Full Title: A multi-centre, double-blind, placebo-controlled, randomised, parallel group clinical trial to evaluate efficacy and safety of Actovegin® in diabetic type 2 patients with symptomatic diabetic perip...
    Medical condition: Diabetic Polyneuropathy
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012685 Diabetic polyneuropathy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001427-40 Sponsor Protocol Number: ION-682884-CS13 Start Date*: 2022-06-07
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: An Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
    Medical condition: Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10057949 Familial amyloid polyneuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Trial now transitioned) ES (Ongoing) SE (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) CY (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-011535-12 Sponsor Protocol Number: Fx1A-303 Start Date*: 2009-08-26
    Sponsor Name:Pfizer Inc.
    Full Title: Open-Label Safety and Efficacy Evaluation of Fx-1006A in Patients with Transthyretin Amyloidosis
    Medical condition: Transthyretin Amyloidosis (ATTR)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10057949 Familial amyloid polyneuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) FR (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004664-18 Sponsor Protocol Number: NEOD001-OLE251 Start Date*: 2017-08-08
    Sponsor Name:Prothena Therapeutics Limited
    Full Title: A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects with Light Chain (AL) Amyloidosis who were previously enrolled in Study NEOD001-201 (PRONTO)
    Medical condition: The objective of this study is to evaluate the long-term safety and efficacy of NEOD001 in subjects with AL amyloidosis who completed Study NEOD001 201
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10036673 Primary amyloidosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) GR (Completed) AT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004670-10 Sponsor Protocol Number: AG10-333 Start Date*: 2020-07-07
    Sponsor Name:Eidos Therapeutics, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Polyneuropathy (ATTRibute-PN Trial)
    Medical condition: Symptomatic Transthyretin Amyloid Polineuropathy (ATTR-PN)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10057949 Familial amyloid polyneuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Prematurely Ended) PT (Prematurely Ended) FR (Completed) BG (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001698-10 Sponsor Protocol Number: ION-682884-CS3 Start Date*: 2020-03-06
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
    Medical condition: Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10057949 Familial amyloid polyneuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) PT (Completed) DE (Completed) ES (Ongoing) IT (Completed) SE (Completed) GR (Prematurely Ended) FR (Completed) CY (Completed) NL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 05:26:50 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA